Carl Zeiss Meditec (ETR:AFX) reported weaker first-half results for fiscal 2025/2026 and outlined a broad restructuring plan aimed at restoring profitability over the next three years, as management pointed to currency headwinds, soft equipment demand and pressure in China’s intraocular lens business.
Chief Executive Andreas Pecher said the company’s top line and earnings in the second quarter “still remained weak,” mainly due to foreign exchange effects and an unfavorable product mix, including lower intraocular lens sales in China. For the first six months, order entry totaled EUR 1.038 billion, down 5.2% year over year, or 2.3% on a currency-adjusted basis. Revenue fell 5.7% to EUR 991 million, or 2.8% on a constant-currency basis.
